找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Mesothelioma; From Research to Cli Giovanni Luca Ceresoli,Emilio Bombardieri,Maurizio Book 2019 Springer Nature Switzerland AG 2019 Lung tu

[復(fù)制鏈接]
樓主: 出租
21#
發(fā)表于 2025-3-25 05:43:20 | 只看該作者
22#
發(fā)表于 2025-3-25 09:57:16 | 只看該作者
23#
發(fā)表于 2025-3-25 13:26:47 | 只看該作者
24#
發(fā)表于 2025-3-25 17:43:35 | 只看該作者
Genetics and Epigenetics of Mesothelioma,ents. These patients are more sensitive to asbestos exposure than those who do not carry such mutations and may benefit of specific treatments. Additionally, epigenetic mechanisms, such as methylation or miRNA alterations, may modify gene expression and drive carcinogenesis. The same abnormalities m
25#
發(fā)表于 2025-3-25 22:23:44 | 只看該作者
26#
發(fā)表于 2025-3-26 02:49:07 | 只看該作者
Pathological Diagnosis of Mesothelioma, between benign and malignant mesothelial proliferations..This chapter is an update of the morphological, immunohistochemical, and molecular features, with particular regard to diffuse malignant mesothelioma diagnosis.
27#
發(fā)表于 2025-3-26 04:24:54 | 只看該作者
28#
發(fā)表于 2025-3-26 10:47:03 | 只看該作者
Role of Metabolic Imaging in Mesothelioma,characterized by the worst prognosis. PET-CT is gradually becoming essential in assessment of tumour response in patients undergoing chemotherapy. Metabolic imaging analysis permits the early identification of non-responders to chemotherapy, avoiding unsuccessful treatment, characterized by importan
29#
發(fā)表于 2025-3-26 15:49:12 | 只看該作者
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma,ideration..Individualization of care for each patient is mandatory in choosing the most appropriate treatment to minimize the complications and to maximize the benefits..The aim of this chapter is to give an overview on the current state of multimodality treatment in MPM.
30#
發(fā)表于 2025-3-26 20:34:11 | 只看該作者
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma,cond-line setting, if clinical trials are not available, single-agent therapy with vinorelbine or gemcitabine may be considered. Alternatively, patients achieving a prolonged benefit from first-line pemetrexed-platinum treatment may be candidate to rechallenge with pemetrexed-based regimens.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-20 23:03
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
依兰县| 嘉义县| 宕昌县| 平泉县| 辽阳县| 濉溪县| 赞皇县| 申扎县| 桃园市| 营山县| 临邑县| 台山市| 榆树市| 融水| 新沂市| 大关县| 天峨县| 平谷区| 呼伦贝尔市| 濉溪县| 准格尔旗| 梧州市| 辽中县| 桑植县| 安平县| 涟源市| 昌图县| 长垣县| 平利县| 灯塔市| 兰溪市| 石门县| 广元市| 措勤县| 海兴县| 博罗县| 谢通门县| 张掖市| 鱼台县| 礼泉县| 吉木萨尔县|